Influence of the Endoscopists and Endoscopic Retrograde CholangioPanceratography

Sponsor
Fundacion Miguel Servet (Other)
Overall Status
Completed
CT.gov ID
NCT04705740
Collaborator
Complejo Hospitalario de Navarra (Other)
2,561
1
2
1299.2

Study Details

Study Description

Brief Summary

Retrospective analysis on a prospective database that analyzes the influence of the number of endoscopists on the Endoscopic Retrograde CholangioPanceratography result.

Condition or Disease Intervention/Treatment Phase
  • Other: ERCP

Detailed Description

The number of Endoscopic Retrograde CholangioPanceratographys (ERCP) performed annually by an endoscopist has been shown to influence the outcomes of the procedure, especially on the papillary cannulation rate and the adverse effects rate. The number of ERCPs performed annually by each endoscopist is directly related to the number of endoscopists who perform this procedure, since the total number of ERCPs performed annually at each center is usually constant.

The hypothesis of this study is that the number of endoscopists who perform ERCP in a hospital influences the results of the procedure, so that the fewer the number of endoscopists the better the results.

To evaluate this hypothesis, the investigators have designed a retrospective study analyzing data from a prospectively filled database, which includes all ERCPs performed in our center from September 2013 to June 2020. For organizative reasons unrelated to the endoscopy unit, in the center it has beed progressively reduced the number of endoscopists who perform ERCP, starting from 5 endoscopists at the beginning of the study to 3 endoscopists at the end of the study inclusion period. In fact, three different periods of similar duration can be distinguished: September 2013 to August 2015 (5 endoscopists), September 2015 to December 2017 (4 endoscopists) and January 2018 to June 2020 (3 endoscopists).

The outcomes obtained with ERCP in these three periods will be analyzed and compared, assessing the cannulation rate and the adverse effects rate as the main comparison parameters.

Study Design

Study Type:
Observational
Actual Enrollment :
2561 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Influence of the Endoscopist Case Volumen on Endoscopic Retrograde CholangioPanceratography Outcomes
Actual Study Start Date :
Sep 1, 2020
Actual Primary Completion Date :
Sep 30, 2020
Actual Study Completion Date :
Oct 31, 2020

Arms and Interventions

Arm Intervention/Treatment
September 2013 to August 2015

5 endoscopists

Other: ERCP
ERCPs performed annually by an endoscopist

September 2015 to December 2017

4 endoscopists

Other: ERCP
ERCPs performed annually by an endoscopist

January 2018 to June 2020

3 endoscopists

Other: ERCP
ERCPs performed annually by an endoscopist

Outcome Measures

Primary Outcome Measures

  1. Papillary cannulation [During the procedure]

    Rate of papillary cannulation.Success in achieving transpapillary access to the bile duct.It has to be confirmed fluoroscopically

  2. Adverse effects [Up to 1 month after intervention]

    Rate of adverse effect assessed by the ASGE classification

Secondary Outcome Measures

  1. Individual adverse effects [Up to 1 month after intervention]

    Rate of individual adverse effect during the intervention

  2. Complexity level of ERCP [During the ERCP procedure]

    Complexity level of ERCP according to ASGE classification of complexity of the endoscopic procedures

  3. Therapeutics performed with ERCP [During the ERCP procedure]

    Techniques used during ERCP

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients undergoing ERCP with written informed consent given

  • Staff allocated in the endoscopy unit

Exclusion Criteria:
  • Rejection to participate in the study

  • ERCP procedures performed by fellows in training

Contacts and Locations

Locations

Site City State Country Postal Code
1 Complejo Hospitalario de Navarra Pamplona Navarra Spain 31008

Sponsors and Collaborators

  • Fundacion Miguel Servet
  • Complejo Hospitalario de Navarra

Investigators

  • Principal Investigator: Juan J Vila, PhD, Complejo Hospitalario de Navarra

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fundacion Miguel Servet
ClinicalTrials.gov Identifier:
NCT04705740
Other Study ID Numbers:
  • NER20
First Posted:
Jan 12, 2021
Last Update Posted:
Jan 12, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fundacion Miguel Servet
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 12, 2021